All News

A global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.

A testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.

The WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.

As estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.

Androgen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.

Liudmila Zhaunova on a global Flo app study linking higher physical activity to lower perimenopause symptom burden.

The 16-item Perimenopause Symptom Scale showed strong reliability and validity among 1255 women aged 35 to 59 years in the United States.

Risa Kagan, MD, on bone health prevention in primary care and why baseline bone density testing should come before age 65.

Patients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.

Risa Kagan, MD, on why the menopause transition is a critical window for bone loss and how women can preserve bone mass.

This FAQ summarizes a Special Report discussion on testosterone pellet therapy in women and advice for hesitant prescribers.

In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.

Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.

This FAQ summarizes a Special Report discussion on off-label testosterone dosing, application, cost, and lab monitoring in women.

This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.

This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.

Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.

HRSA will award up to $1 million to a single organization to update the Women's Preventive Services Guidelines through the new WISH program.

Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.

Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.

CMS' proposed G-codes, which experts stated would cause confusion in combination with the AMA's proposed codes, were not included in the final fee schedule for 2027, according to ACOG.

Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.

Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.

Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.

Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.

A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.

Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.

The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.